<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112519">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01638455</url>
  </required_header>
  <id_info>
    <org_study_id>Masimo-Noninvasive 1</org_study_id>
    <nct_id>NCT01638455</nct_id>
  </id_info>
  <brief_title>Pulse CO-Oximetry Noninvasive Monitoring and Laboratory Measurements of Subject Blood Samples</brief_title>
  <official_title>Noninvasive Parameter Testing With Pulse CO-Oximetry and Measurement of Blood Constituents With In-Vitro Analyzers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masimo Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masimo Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Characterize Masimo noninvasive technology in spot check reading on subjects and make
      comparison to invasive blood sampling tested on reference analyzers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Noninvasive readings from subjects done according to manufacturer's directions of use
      compared to simultaneously derived blood samples measured on in vitro analyzers
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Various Comorbidities</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Noninvasive monitoring, blood sampling</intervention_name>
    <description>Noninvasive monitoring, blood sampling</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples, venous or capillary
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects from Outpatient clinics and health fairs
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female of any age â‰¥ 3 kg.

          -  Subjects may include healthy volunteers, outpatient or inpatient populations

        Exclusion Criteria:

          -  Subjects with skin abnormalities at the planned application sites that may interfere
             with sensor application or trans-illumination of the site, such as burns, scar
             tissue, nail polish, acrylic nails, infections, etc.

          -  Subjects deemed not suitable for study at the discretion of the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Holody, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Masimo Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark Holody, PhD</last_name>
    <phone>949-297-7311</phone>
    <email>mholody@masimo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dawn Fatheree</last_name>
    <phone>949-297-7549</phone>
    <email>dfatheree@masimo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Masimo</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92618</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Holody, PhD</last_name>
      <phone>949-297-7311</phone>
      <email>mholody@masimo.com</email>
    </contact>
    <contact_backup>
      <last_name>Dawn Fatheree</last_name>
      <phone>949-297-7549</phone>
      <email>dfatheree@masimo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Nitin Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <lastchanged_date>July 10, 2012</lastchanged_date>
  <firstreceived_date>July 9, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
